← Leaderboards
Raymond E Meyn
University Of Texas Md Anderson Can Ctr
$4,117,563
Attributed
$4,117,563
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $539.2K · FY2005–15$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$4,117,563 · 4
By mechanism
R01$2,690,270 · 2
P01$1,252,370 · 1
R41$174,923 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Md Anderson Can Ctr
Same institution · by research overlap
- K Kian Ang$2,378,003
- Jack Roth$8,028,008
- Konstantin V Sokolov$9,178,408
- Vinay K Puduvalli$3,692,967
- Xifeng Wu$28,679,533
Others in their field
Top investigators on “Apoptosis”
- David Heimbrook · Leidos Biomedical Research, Inc.$49,205,802
- Jay A Nelson · Oregon Health & Science University$45,942,124
- John C Reed · University Of Texas Md Anderson Can Ctr$34,437,189
- John A Tainer · Scripps Research Institute$30,637,655
- Henry Shelton Earp · Univ Of North Carolina Chapel Hill$28,872,594
- John D Minna · University Of Texas Sw Med Ctr/Dallas$27,317,167
Research focus
ApoptosisGene ExpressionCell LineNeoplasm /Cancer Radiation TherapyWestern BlottingsNeoplastic CellTumorOncogenesMolecularTumor Suppressor GenesGlutathioneSignal TransductionFundingBcl2 Gene /ProteinBaseMitochondriaTissue /Cell CultureIn VivoNormal Tissue MorphologyIntracellular TransportIn VitroAntioxidantsAntineoplasticsFuture
Grant awards (19)
Extension of Radiotherapy Research$295,023
R01 · FY2015 · CA · contact PI
Extension of Radiotherapy Research$285,013
R01 · FY2014 · CA · contact PI
Extension of Radiotherapy Research$275,125
R01 · FY2013 · CA · contact PI
GENE THERAPY STRATEGIES TO RADIOSENSITIZE HUMAN TUMOR CELLS$282,496
P01 · FY2008 · CA · contact PI
GENE THERAPY STRATEGIES TO RADIOSENSITIZE HUMAN TUMOR CELLS$281,477
P01 · FY2007 · CA · contact PI
Anticancer Drug Resistance by Bcl-2 Oncogene Expression$257,716
R01 · FY2007 · CA · contact PI
Anticancer Drug Resistance by Bcl-2 Oncogene Expression$265,413
R01 · FY2006 · CA · contact PI
GENE THERAPY STRATEGIES TO RADIOSENSITIZE HUMAN TUMOR CELLS$163,275
P01 · FY2006 · CA · contact PI
Anticancer Drug Resistance by Bcl-2 Oncogene Expression$271,800
R01 · FY2005 · CA
GENE THERAPY STRATEGIES TO RADIOSENSITIZE HUMAN TUMOR CELLS$159,568
P01 · FY2005 · CA
Anticancer Drug Resistance by Bcl-2 Oncogene Expression$294,300
R01 · FY2004 · CA
GENE THERAPY STRATEGIES TO RADIOSENSITIZE HUMAN TUMOR CELLS$155,190
P01 · FY2004 · CA
ANTICANCER DRUG RESISTANCE BY BCL2 ONCOGENE EXPRESSION$254,059
R01 · FY2002 · CA
ROLE OF PROGRAMMED CELL DEATH IN RADIATION RESPONSE$0
P01 · FY2002 · CA
ANTICANCER DRUG RESISTANCE BY BCL2 ONCOGENE EXPRESSION$248,575
R01 · FY2001 · CA
ROLE OF PROGRAMMED CELL DEATH IN RADIATION RESPONSE$0
P01 · FY2001 · CA
ANTICANCER DRUG RESISTANCE BY BCL2 ONCOGENE EXPRESSION$243,246
R01 · FY2000 · CA
ROLE OF PROGRAMMED CELL DEATH IN RADIATION RESPONSE$210,364
P01 · FY2000 · CA
TUMOR CELL RADIOSENSITIZATION BY ADENOVIRAL-MEDIATED P16$174,923
R41 · FY2000 · CA